Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury

British Journal of Pharmacology

Volumn 155, Issue 1, 2008, Pages 93-102

  Carter, J M ^a   Buerke, U ^a   Rossner E ^a   Russ, M ^a   Schubert, S ^a   Schmidt, H ^a   Ebelt, H ^a   Pruefer, D ^b   Schlitt, A ^a   Werdan, K ^a   Buerke, M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Aprotinin; Ischaemia reperfusion; Leukocytes; Myocardial reperfusion injury; Neutrophil adherence; Serine protease inhibitor

Indexed keywords

APROTININ; CREATINE KINASE; MYELOPEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; MALE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; APROTININ; CELL ADHESION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HEMODYNAMICS; LEUKOCYTE COUNT; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; NEUTROPHIL INFILTRATION; NEUTROPHILS; RABBITS; SERINE PROTEINASE INHIBITORS; TIME FACTORS;

EID: 50249173893     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.223     Document Type: Article

References (35)

1. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC (2001). Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 122: 123-128.
2. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP et al. (2000). An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 120: 361-369.
3. Barnes JA, Singh S, Gomes AV (2004). Protease activated receptors in cardiovascular function and disease. Mol Cell Biochem 263: 227-239.
4. Buerke M, Murohara T, Lefer AM (1995a). Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393-402.
5. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM (1995b). Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 92: 8031-8035.
6. Buerke M, Schwertz H, Langin T, Buerke U, Prondzinsky R, Platsch H et al. (2006). Proteome analysis of myocardial tissue following ischemia and reperfusion - effects of complement inhibition. Biochem Biophys Acta 1764: 1536-1545.
7. Buerke M, Schwertz H, SeitzW, Meyer J, Darius H (2001). Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol 167: 5375-5380.
8. Buerke M, Weyrich AS, Zheng Z, Gaeta FC, Forrest MJ, Lefer AM (1994). Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats. J Clin Invest 93: 1140-1148.
9. Bull DA, Maurer J (2003). Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 75: S735-S739.
10. Clarke M, Bennett M, Littlewood T (2007). Cell death in the cardiovascular system. Heart 93: 659-664.
11. Day JR, Landis RC, Taylor KM (2006a). Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth 10: 132-142.
12. Day JR, Taylor KM, Lidington EA, Mason JC, Haskard DO, Randi AM et al. (2006b). Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 131: 21-27.
13. Dietrich W, Busley R, Kriner M (2006). High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 103: 1074-1081.
14. Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJ, O'Donnell AP, Shorten GD (2004). Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth 51: 1002-1009.
15. Hausenloy DJ, Yellon DM (2007). The evolving story of 'conditioning' to protect against acute myocardial ischaemia-reperfusion injury. Heart 93: 649-651.
16. Hordijk PL (2006). Endothelial signalling events during leukocyte transmigration. FEBS J 273: 4408-4415.
17. Jormalainen M, Vento AE, Lukkarinen H, Kaapa P, Kyto V, Lauronen J et al. (2007). Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass. J Cardiothorac Vasc Anesth 21: 224-231.
18. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A et al. (2006). A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46: 327-338.
19. Khan TA, Bianchi C, Voisine P, Feng J, Baker J, Hart M et al. (2004). Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 128: 602-608.
20. Kher A, Meldrum KK, Hile KL, Wang M, Tsai BM, Turrentine MW et al. (2005). Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. J Thorac Cardiovasc Surg 130: 662-669.
21. Kunapuli S, Rosanio S, Schwarz ER (2006). 'How do cardiomyocytes die?' apoptosis and autophagic cell death in cardiac myocytes. J Card Fail 12: 381-391.
22. Lazar HL, Bao Y, Tanzillo L, O'Gara P, Reardon D, Price D et al. (2005). Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 20: 519-523.
23. Leytin V, Allen DJ, Lyubimov E, Freedman J (2007). Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. Br J Haematol 136: 762-764.
24. Mangano DT, Tudor IC, Dietzel C (2006). The risk associated with aprotinin in cardiac surgery. N Engl J Med 354: 353-365.
25. Mirabet M, Garcia-Dorado D, Ruiz-Meana M, Barrabes JA, Soler-Soler J (2005). Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. J Mol Cell Cardiol 39: 277-283.
26. Mullane KM, Westlin W, Kraemer R (1988). Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. Ann NY Acad Sci 524: 103-121.
27. Park HY, Song MG, Lee JS, Kim JW, Jin JO, Park JI et al. (2007). Apoptosis of human neutrophils induced by protein phosphatase 1/2A inhibition is caspase-independent and serine protease-dependent. J Cell Physiol 212: 450-462.
28. Pham CT (2006). Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 6: 541-550.
29. Pruefer D, Buerke U, Khalil M, Dahm M, Darius H, Oelert H et al. (2002). Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart. J Thorac Cardiovasc Surg 124: 942-949.
30. Raff MC (1992). Social controls on cell survival and cell death. Nature 356: 397-400.
31. Sabri A, Alcott SG, Elouardighi H, Pak E, Derian C, Andrade-Gordon P et al. (2003). Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem 278: 23944-23954.
32. Thornberry NA, Rosen A, Nicholson DW(1997). Control of apoptosis by proteases. Adv Pharmacol 41: 155-177.
33. Weiss SJ (1989). Tissue destruction by neutrophils. N Engl J Med 320: 365-376.
34. Williams FM (1996). Neutrophils and myocardial reperfusion injury. Pharmacol Ther 72: 1-12.
35. Yaoita H, Ogawa K, Maehara K, Maruyama Y (1998). Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97: 276-281.